Table 2.
Prognostic factors and treatment-effect modifiers included in the MAIC analysis
| Factors | Prognostic factor according to clinical experts | Effect-modifier according to clinical experts | Prognostic factors in the DREAMM-2 data | Available for comparison in STORM Part 2 | Included in the MAIC models |
|---|---|---|---|---|---|
| Age | ✓ | ✓ | ✓ | ✓ | |
| Sex | ✓ | ✓ | ✓ | ||
| ECOG status | ✓ | ✓ | ✓ | ✓ | |
| Comorbidities (renal, liver, or frailty index) | ✓ | ✓ | ✓ | ||
| Cytogenetic factors | ✓ | ✓ | ✓ | ✓ | ✓ |
| R-ISS stage | ✓ | ✓ | ✓ | ✓ | ✓ |
| Extramedullary disease | ✓ | ✓ | |||
| Serum BCMA levels | ✓ | ||||
| Number of prior lines of therapy | ✓ | ✓ | ✓ | ✓ | ✓ |
| Refractory status | ✓ | ✓ | ✓ | ✓ | |
| Lytic bone lesions at baseline | ✓ |
BCMA, B-cell maturation antigen; ECOG, Eastern Cooperative Oncology Group; R-ISS, revised international staging system; MAIC, matching-adjusted indirect comparison